�������ϲ�

The �������ϲ� recently signed its first intellectual property license agreement with Satya Diagnostics — a company that recently received $100,000 in  to help it achieve its goal of improving cancer detection and treatment in communities across the world.

The newly licensed technology, a novel blood-based biomarker test, was developed by UNE researcher Srinidi Mohan, Ph.D., in collaboration with MaineHealth clinician Susan Miesfeldt, M.D., and aims to revolutionize diagnosis and treatment for patients with aggressive cancers like triple-negative breast cancer and ovarian cancer. 

Research indicates that more than 9 in 10 women with breast cancer survive for five or more years when diagnosed at the earliest stage, but this survival rate plummets to just 3 in 10 when the cancer is caught in more advanced stages. Treatment decision-making for breast cancer, especially for aggressive forms of the disease, is limited by the inability to quickly determine treatment effectiveness and optimize care — an issue this technology can solve.

The licensed technology centers on the use of the biomarker Nw-hydroxy-L-Arginine, or NOHA, to determine the presence of high-risk cancers, allowing for timelier disease control through blood testing to monitor and manage treatment of aggressive cancers like triple-negative breast cancer and ovarian cancer — a disease difficult to detect in its earliest stages.

“The NOHA assay could play a transformative role in cancer care, with likely utility in early detection, treatment response monitoring, and long-term surveillance, collectively aimed at improving the outcome of those facing a cancer diagnosis,” Miesfeldt said. “As an easy-to-use blood tes